On February 22, Sinopharm Modern issued an announcement stating that the company and its wholly-owned subsidiary Sinogong Co
Kangchen Pharmaceutical's clinical application for the import of teriparatide similar drugs has been accepted
Time of Update: 2022-02-24
Kangchen Pharmaceutical is a company that produces the same teriparatide biosimilar in the same water injection pen formulation as Lilly’s original research.
Bio-similar drugs accelerate overtaking, Qilu breaks the game, Biotech loses weight
Time of Update: 2022-01-02
> . The resulting situation is that as of the first half of this year, the first rituximab biosimilar drug has completed the medical insurance opening of 30 domestic provinces and cities, and more than 70
First domestic product: Chia Tai Tianqing declares "Mepolizumab" similar drug
Time of Update: 2021-11-04
From CDE official website Mepolizumab was developed by GlaxoSmithKline and was approved by the FDA in November 2015 to treat severe and eosinophilic phenotypic asthma in patients 12 years of age and older.
The price difference of similar drugs exceeds 2 times, and it needs to be reduced by 30% or 2 times the lowest price!
Time of Update: 2021-07-24
In addition, for newly-listed medicines and medical consumables to be purchased online in Jiangxi Province, manufacturers will register dynamically, and related products will also be included in the candidate list after publicity .
Cervical cancer market: Bio-similar drugs are on the rise, and vaccines differ significantly in domestic and foreign patterns
Time of Update: 2021-04-17
methods and routes have gradually improved, and drug intervention has become an important means of cervical cancer treatment. Chemotherapy is gradually participating in the comprehensive treatment of cervical cancer in the form
The price difference of similar drugs is more than 2 times, and it needs to be reduced by 30% or 2 times the lowest price!
Time of Update: 2021-03-24
stipulates that when the price of similar products is 2 times or more than the lowest price, it must be reduced by 30% or reduced to 2 times the lowest price. This requirement was not mentioned
The Grigg Ingeham biosynthic drug BI 695501 is similar in effectiveness and safety to Symele
Time of Update: 2021-02-21
contributing to the long-term sustainability of the healthcare system." This Phase III clinical study was a randomized, double-blind, parallel group, multiple administration, and positive control drug study, in 645 cases diagnosed with moderate
Domestic single anti-bio-similar drugs to seize the original research 20 billion market opened
Time of Update: 2021-02-19
varieties accounted for more than 60%. Data show that a total of 39 imported antibody drugs registered for clinical use in China. From 2018 to the end of August 2020, 26 imported antibody drugs were approved, more than
Industry barriers are too high Bio-similar drug research and development is booming
Time of Update: 2021-02-06
from the current situation, the domestic market biosynthic drug research and development mainly concentrated in lytoxi monoanti, curt bead monoanti, beval bead mono-resistance and other 6 major mono-resistance varieties.
The Troika was besieged by bio-similar drugs, and Roche and Pfizer responded to what to do next
Time of Update: 2021-01-27
renegotiable, again reduce the price to complete the renewal of health insurance, according to IQVIACHAPTM statistics, 2018 and 2019 Quto Zhuzhu single resistance sales in China amounted to about 2.73 billion yuan and 4.57 billion yuan, respectively
How long can Zilu, Zinda and other bio-similar drugs enjoy "rich" pricing? This enterprise quietly
Time of Update: 2021-01-19
/> And the price is a key factor in the development of the biosynthic drug market, before the collection, different products of various enterprises have played a different strategy, E drug managers have been approved for sale of several similar drug
Nature: The psychedelic drug Iberg alkaline similar to TBG is expected to treat addiction and depression without side effects
Time of Update: 2020-12-27
December 14, 2020 /--- In a new study, researchers at the University of California, Davis, have developed a non-hallucinogenic version of the psychedelic drug ibogaine, which has the potential to treat addiction, depression and other mental illnesses.
China's bio-similar drugs "explosion", market competition is becoming more and more intense
Time of Update: 2020-11-18
Pharmaceutical Network Industry Dynamics Recently, Xinda Bio announced that its Adamo single anti-biosimilar drug (Su Lixin) has been approved for the market for the treatment of rheumatoid arthritis, strong vertebrate and psoriasis.
China's biological similar drug concentration "explosion" within two years 7 approved is moving towards international development
Time of Update: 2020-11-15
monoanti, beval bead monoanti, Adamo single resistance and other world-best-selling drugs. Taking into account the requirements of the State Drug Administration of China to "support the imitation of biosimilar drugs and pharmaceutical combination
If bio-similar drugs gather in Xinda, Qilu... who can win?
Time of Update: 2020-11-10
alternativeness of specific products". The response also mentioned that, in accordance with the Notice on the Inclusion of Negotiated Drugs in Category B for 2019, "if any generic named drug (generic) from other production enterprises is automatically
Two types of puzzles remain to be solved behind bio-similar drugs or "bend oversized" shortcuts for enterprises
Time of Update: 2020-11-09
Conference on Bio-Product Innovation and Industrialization, scholars and business people expounded the definition of biosynthic drugs and related policies and market conditions. 2015, there is no clear definition of biosynthic drugs in China
If bio-similar drugs gather in Xinda, Qilu... who can win?
Time of Update: 2020-11-06
drugs, the stability of enterprise capacity and supply chain, and the clinical alternativeness of specific products". The response also mentioned that, in accordance with the Notice on the Inclusion of Negotiated Drugs in Category B for 2019
China's bio-similar drug development to meet the "golden age" Fuhong Hanxuan took the lead in the breakout!
Time of Update: 2020-10-15
. , according to Sina Pharmaceuticals, Hanqu ®'s domestic price is 1688 yuan / bottle (150mg / bottle). The original health care price for Hessetin in 2017 was 7,600 yuan per bottle (440 mg/bottle), and in 2019 the National Health Insurance
New drug for special dermatitis! Otsuka outside the PDE4 inhibitor defamilast applied for listing
Time of Update: 2020-10-14
and itching symptoms in patients with specific dermatitis. the drug regulatory reform, Dabito was approved ® china two years in advance, providing New Treatment Options for Chinese patients. Dabito® is an all-human monoclonal antibody, through
